Intracerebroventricularly infused hypertonic saline elicits sympathoexcitatory and pressor effects. To clarify the mechanisms mediating these effects, we evaluated blood pressure (BP), heart rate (HR), and renal sympathetic nerve activity (RSNA) responses to intracerebroventricular administration of 0.3 M NaCI, ouabain, and rat hypothalamic and pituitary extracts containing ouabain-like activity (OLA) 
H igh sodium intake exaggerates the development of hypertension in rats genetically predisposed to hypertension; this response is partially due to central effects increasing sympathetic outflow and blood pressure (BP).12 The primary mechanisms through which high sodium intake causes these sympathoexcitatory responses have so far not been elucidated. One possibility is that high sodium intake intermittently or chronically increases sodium concentrations in the cerebrospinal fluid (CSF), resulting in an activation of not only central osmotic receptors but also central sodium receptors,3'4 leading to increased sympathetic outflow and arterial BP. We recently provided indirect evidence that brain ouabain-like activity (OLA) may play a primary role in the different responses to high sodium intake in spontaneously hypertensive rats (SHR) versus Wistar-Kyoto (WKY) control rats. 5 In the present study, we provide more direct evidence for a possible role of brain OLA in the sympathoexcitatory and pressor responses to increases in central sodium.
Chronic intracerebroventricular infusion with hypertonic saline elevates BP in normotensive rats.3 In anesthetized rats, intracerebroventricular infusion with hypertonic saline increases BP, heart rate (HR), and sympathetic nerve activity.6 These responses depend on an increase in the Na+ concentration in the cerebrospinal fluid and not on changes in osmolarity.78 Part of the early pressor response results from increased arginine vasopressin (AVP) release, but the subsequent maintenance of pressor effect is associated with increased sympathetic nerve activity and can be abolished by ganglionic blockade34, 8 
Surgical Procedure
Implantation of a chronic intracerebroventricular cannula under sodium pentobarbital anesthesia and verification of the placement were described previously. 5 Briefly, via a stereotaxic frame, a 23-gauge needle was fixed on the skull of the rat with acrylic cement (over the left lateral ventricle, 0.3 mm posterior and 1.4 mm lateral to the bregma). The lower end of the guide needle was approximately 0.5 mm above the ventricle, and the upper end was sealed with a stylet. At least 1 week after the surgery, with the rats under halothane anesthesia, catheters were placed in the right femoral artery and jugular vein. With an additional intravenous injection of sodium pentobarbital, a pair of platinum electrodes was placed around the left renal nerve through a left flank incision. The electrodes and the catheters were then tunneled under the skin to the back of the neck. After recovery from the anesthesia (5 hours), the rats were placed in a small cage in which they could move back and forth for the experiments.
BP, HR and RSNA Recordings
As described previously,5 the intra-arterial catheter was connected to a transducer, and BP and HR were monitored through a polygraph (model 7E, Grass Instrument Co., Quincy, Mass.) and a Grass 7P44 tachograph. The electrodes were connected to a Grass P511 bandpass amplifier, and RSNA (spikes per second) was counted by means of a nerve traffic analyzer. The AVP antagonist injected intravenously at 30 a£g/kg caused transient decreases in BP, HR, and RSNA that were not statistically significant compared with the resting levels. When intracerebroventricular infusion of 0.3 M NaCl was performed 5 minutes after the intravenous injection of the AVP antagonist, the initial decrease in HR was no longer observed. BP, HR, and RSNA increased simultaneously within 2 minutes after infusion, reached plateau levels, and returned to the baselines 2-3 minutes after the termination of infusion (Figure 1) . The peak values of responses were significantly higher than the resting levels ( Figure 2 
Intracerebroventricular Ouabain
Intracerebroventricular ouabain 5 minutes after intravenous AVP antagonist injection increased BP, HR, and RSNA in a dose-related fashion. The responses began 1 minute after ouabain injection (Figure 1) 
Discussion
The present study provides a major new finding: intracerebroventricular administration of ouabain, brain OLA, and hypertonic saline causes similar sympathoexcitatory and pressor responses, which all can be blocked by DAF fragments.
Similar to our previous studies in SHR and WKY rats,5 in the present study in conscious Wistar rats, intracerebroventricular injection of ouabain increased BP, HR, and RSNA in a dose-dependent manner. We also show that similar sympathoexcitatory and pressor responses are elicited by intracerebroventricular rat hypothalamic/pituitary extracts containing ouabain-like activity. Intracerebroventricular OLA also induced behavioral changes similar to those induced by ouabain. The magnitudes of increases in BP and RSNA by intracerebroventricular OLA equivalent to 1 ,gg ouabain were approximately 30% smaller than the increase induced by 1 ,tg ouabain per se. Therefore, the Na+,K+-ATPase-inhibiting effect of ouabain versus OLA may not be identical when applied in vitro versus in vivo. Since Na+,K+-ATPase from rat kidney was used for quantitation of OLA and brain ATPase is different from kidney ATPase in terms of their catalytic subunit,18 it is also possible that OLA binds to brain and kidney ATPase with a different affinity. Takahashi et al910 reported in anesthetized rats that 1-10 ,jg ouabain was required intracerebroventricularly to elicit significant pressor and tachycardia responses9 but only 10 ng/10 ,ul rat brain OLA was needed intracerebroventricularly to induce similar responses.10 In addition to the fact that conscious versus anesthetized animals were used, the discrepancy may be due to the different methods of OLA quantitation, i.e., assay for Na+,K+-ATPase activity (present study) versus quantitation of OLA by an ouabain radioimmunoassay.10 The amounts of ouabain or OLA administered may appear large (0.3-1.0 ,ug).
However, it is rather likely that at the actual site of action ouabain and OLA exert their effects in concentrations several orders of magnitude lower than the ones injected intracerebroventricularly. To place these amounts in a more physiological perspective, the concentration of OLA (as assessed by assay for Na+,K+-ATPase activity) amounts to 3-4 ,ug/g in the hypothalamus and 40-60 ,ug/g in the pituitary (F.H.H. Leenen, unpublished data).
After pretreatment with the AVP antagonist, intracerebroventricular infusion of hypertonic saline increased BP, HR, and RSNA similar to the responses induced by ouabain as well as brain OLA. Several studies have demonstrated that intracerebroventricular administration of hypertonic saline induces sympathoexcitatory and pressor effects.6, '9,20 In anesthetized rats with an intact arterial baroreflex function,6 intracerebroventricular infusion of 0.3 M NaCl caused elevation of BP and delayed increases in HR and sympathetic nerve activity. However, after intravenous administration of 30 ,ug/kg AVP antagonist, which blocks the pressor effects of vasopressin,6 the delay in sympathetic nerve activity and HR responses was absent, and intracerebroventricular infusion of the hypertonic saline caused concomitant increases in sympathetic nerve activity, BP, and HR. Therefore, the initial part of the pressor response appears to be a result of stimulation of by guest on October 19, 2017 http://circres.ahajournals.org/ Downloaded from AVP release via activation of brain osmotic or sodium receptors,21 and the maintenance of the response appears to be independent of AVP and associated with sympathoexcitatory effects of hypertonic saline itself. Results from the current study in conscious rats are consistent with these findings.
In rats pretreated with AVP antagonist, intracerebro- OLA, indicating that ouabain, as an analogue of digitalis glycosides,13 and OLA may both be recognized by and bound to DAF fragments. This is consistent with a previous report12 that DAF fragments were clinically effective in the treatment of digitalis intoxication caused by overdoses of digoxin, digitoxin, and other cardiac glycosides. Because of the relatively small size of the DAF fragments, they can diffuse rapidly into the interstitial space and bind free glycosides, and because the affinity of the glycosides for DAF fragments is higher than for Na+,K+-ATPase, the glycoside molecules will be moved from the cell membrane into the extracellular space12,24 with minimal reassociation with the inhibiting site on the a-subunit of NaX,K+-ATPase.12
No study has so far evaluated the possible role of central OLA in the sympathoexcitatory and pressor effects of centrally administered sodium, because, at least in part, no specific antagonist was available. Canrenone is a primary metabolite of the antimineralocorticoid spironolactone. Studies in human red blood cells showed that canrenone is able to restimulate the blocked Na+-K+ pump when the cells are treated with high concentrations of ouabain.2 However, canrenone is also a partial agonist of cardiac glycosides and enhances the inhibition of the Na+-K+ pump by low doses of ouabain in these cells at physiological cell Na+ levels.25 Nonetheless, it lowered the BP in rats made hypertensive by reduction of renal mass,26,27 presumably by antagonizing the effects of increased endogenous OLA.
There has been no information, so far, regarding the release of brain OLA by acute or chronic elevation of CSF sodium. Beasley 
